AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Legacy Capital Wealth Partners LLC

Legacy Capital Wealth Partners LLC grew its holdings in AstraZeneca PLC (NASDAQ:AZN) by 3.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,526 shares of the company’s stock after acquiring an additional 286 shares during the quarter. Legacy Capital Wealth Partners LLC’s holdings in AstraZeneca were worth $624,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Martin Investment Management LLC lifted its holdings in shares of AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after purchasing an additional 7,615 shares during the period. Nordea Investment Management AB acquired a new stake in shares of AstraZeneca during the fourth quarter worth about $754,000. Diversify Wealth Management LLC lifted its holdings in shares of AstraZeneca by 3.6% during the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock worth $295,000 after purchasing an additional 153 shares during the period. Ameritas Advisory Services LLC lifted its holdings in shares of AstraZeneca by 25.9% during the fourth quarter. Ameritas Advisory Services LLC now owns 9,487 shares of the company’s stock worth $622,000 after purchasing an additional 1,949 shares during the period. Finally, Integrated Advisors Network LLC lifted its holdings in shares of AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock worth $3,398,000 after purchasing an additional 13,860 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. UBS Group raised AstraZeneca from a “neutral” rating to a “buy” rating in a report on Thursday. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Finally, Morgan Stanley assumed coverage on AstraZeneca in a research report on Wednesday. They set an “overweight” rating for the company. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Down 1.2 %

Shares of AZN stock opened at $73.58 on Friday. The stock has a 50 day moving average of $68.07 and a 200 day moving average of $73.43. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The stock has a market cap of $228.18 billion, a P/E ratio of 32.56, a P/E/G ratio of 1.20 and a beta of 0.46. AstraZeneca PLC has a twelve month low of $61.77 and a twelve month high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.55%. As a group, sell-side analysts expect that AstraZeneca PLC will post 4.66 EPS for the current year.

AstraZeneca Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Monday, March 24th. Stockholders of record on Friday, February 21st will be given a $1.03 dividend. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from AstraZeneca’s previous semi-annual dividend of $0.49. This represents a dividend yield of 2%. AstraZeneca’s payout ratio is 43.36%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.